Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.

Autor: Egeberg A; Department of Dermatology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Kristensen LE; The Parker Institute, University of Copenhagen & Bispebjerg University Hospital, Copenhagen, Denmark., Puig L; Department of Dermatology, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain., Rich P; Oregon Dermatology and Research Center, Portland, Oregon, USA., Smith SD; The Dermatology and Skin Cancer Centre, Sydney, New South Wales, Australia.; The Sydney Adventist Hospital Clinical School, ANU Medical School, ANU College of Health and Medicine, The Australian National University, Canberra, Australian Capital Territory, Australia., Garrelts A; Eli Lilly and Company, Indianapolis, Indiana, USA., See K; Eli Lilly and Company, Indianapolis, Indiana, USA., Holzkaemper T; Eli Lilly and Company, Indianapolis, Indiana, USA., Fotiou K; Eli Lilly and Company, Indianapolis, Indiana, USA., Schuster C; Eli Lilly and Company, Indianapolis, Indiana, USA.; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Jazyk: angličtina
Zdroj: The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2263108. Date of Electronic Publication: 2023 Oct 02.
DOI: 10.1080/09546634.2023.2263108
Abstrakt: Background: Available network meta-analyses (NMAs) comparing the efficacy of biologics in nail psoriasis (NP) have not included recently approved biologics such as bimekizumab nor have they provided comparisons up to 1 year.
Objective: We conducted two NMAs that update and extend results from a previous NMA comparing biologics for achieving complete resolution of NP.
Methods: Bayesian NMAs were performed using a generalized linear model with a logit link to model the binary outcome of nail clearance at weeks 24-28 and 48-52.
Results: For the NMA at weeks 24-28, which included seven biologics and placebo, the absolute probability of achieving complete resolution of NP was highest for ixekizumab (46.4%; 95% credibility interval [CrI] 35.2-58.0), followed by brodalumab (37.1%; 95% CrI 17.1-62.2) and bimekizumab (30.3%; 95% CrI 12.7-53.9). For the NMA at weeks 48-52, which included six biologics, the absolute probability was highest for ixekizumab (77.2%; 95% CrI 51.1-93.4), followed by adalimumab (75.6%; 95% CrI 61.5-87.3) and brodalumab (71.9%; 95% CrI 38.4-93.2).
Conclusion: Among biologics included in these two NMAs, ixekizumab has the highest absolute probability of achieving complete resolution of NP. Results may help to inform treatment decisions for patients with NP.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje